As LPII pursues opportunities and moves forward in an environment of challenge and change, the Company continues to strengthen its governance accountability and oversight by having an experienced and independent Board of Directors. LPII remains at the forefront in establishing, maintaining and strengthening all aspects of its corporate governance. The Board of Directors and the Executive Management Team at LPII are committed to responding to the needs and opportunities created by a dynamic and challenging marketplace.
Jason C. Katzaroff – CHAIRMAN, CEO & Founder
Jason C. Katzaroff is founder, CEO and chairman of Leading Pharmaceutical Isotope Industry. A serial entrepreneur who started his first company importing minerals and pewter from Brazil while in high school in southern California, Mr. Katzaroff is constantly searching for outstanding opportunities. Hired straight out of college Mr. Katzaroff was a financial consultant for Wall Street firms Bateman Eichler, Smith Barney and EFHutton. Since 1990, he has been responsible for corporate engineering, senior-level corporate strategy, fostering investment bank relationships, and has served as a senior financial advisor for numerous start-ups and development stage companies.
A strong desire to make an unshakable impact in the fight against cancer led Mr. Katzaroff to found LPII in 2006. Katzaroff serves on the Board of Directors for the Washington Biotechnology and Biomedical Association (WBBA), is Vice Chairman of Go Nuclear Inc. and past Vice Chairman of the Fighting Children’s Cancer Foundation.
Dr. Carlton Gadwell – DIRECTOR
Dr. Carlton Gadwell joined Leading Pharmaceutical Isotope Industry as a director in 2006. Dr. Cadwell brings over 30 years of experience in business management, strategic planning, and implementation. He co-founded Gadwell Laboratories, Inc. in 1979 and has served as its President since its inception. Gadwell Laboratories, Inc. is a major international provider of neurodiagnostic medical devices.
After receiving his bachelor’s degree from the University of Oregon in 1966 and a doctoral degree from the University of Washington in 1970, he began his career serving in the United States Army as a dentist for 3 years. From 1973 to 1980, Dr. Gadwell practised dentistry in private practice and since has started several businesses.
Thompson J. Clement – DIRECTOR
Tom Clement is currently the CEO of Aqueduct Neuroscience Technology, Inc. Aqueduct is developing a novel implantable shunt for treating hydrocephalus, a condition that causes a person not to be able to reabsorb cerebrospinal fluid. Existing technologies fail at an alarming rate, often requiring the pediatric patient to have as many as four brain surgeries by the time they are 20 years old.
Clement was the CEO of Cardiac Insight, Inc. from March of 2011 through December, 2012. Cardiac Insight is developing a highly accurate Atrial Fibrillation monitor to address the “silent” a-fib market, those patients with undiagnosed, difficult to detect atrial fibrillation which is a huge risk factor for stroke, but when diagnosed and treated allows the patient’s risk factor to be reduced to normal. At Cardiac Insight, Clement was responsible for all operations. He helped to raise $1.2 million dollars, built a team of product developers, and led the efforts to develop the product and submit it to FDA for clearance in the US.
Clement previously was employed at the University of Washington’s Center for Commercialization where he was the Director of New Ventures – Life Sciences. His responsibilities there included identification of promising technologies that have potential to be commercialized via a new start-up. In his role, he worked with researchers and UW personnel to advance the business plans for the identified commercial prospects in areas spanning market strategy, regulatory strategy, identification of management, and early stage financing.
In October 1998 Clement co-founded Pathway Medical Technologies, Inc. where he served as the company CEO until September 2008. At Pathway he led a talented management team as the company developed and brought to market its flagship product, the Jetstreamtm System for treatment of peripheral arteries. As CEO, Clement had active involvement in clinical and regulatory strategy, product development, operations and quality assurance. He was also responsible for business development and financing, where he successfully raised more than $84 million for Pathway. In September, Clement assumed the role of Chairman of the Board. Pathway was sold to Bayer Germany in August of 2011.
Clement has over 32 years’ experience in product development engineering, engineering management, and senior management. Previously, Clement was a founding employee of Heart Technology which grew to more than $100 million in revenue and 550 employees. There he spent 12 years in senior management roles. When Heart Technology was acquired by Boston Scientific, Clement became responsible for the emerging cardiovascular technologies group of the Scimed division of Boston Scientific.
Clement has a Master of Science in Electrical Engineering from the University of Washington. He is the recent Chairman of the Board of Directors for the Washington Biotechnology and Biomedical Association (WBBA), and he remains on the Executive Committee of the WBBA. He also has positions on the Visiting Committee for the University of Washington Educational Outreach Programs, and the Advisory Board to the University of Washington’s Master Degree in Medical Engineering. He sits on the boards of several startup companies and organizations including the Bothell Innovation Partnership Zone, and WINGS Angel Investor organization for medical device angel investing. Clement has also been appointed by Governor Gregoire to the Washington Global Health Technologies Competitiveness Board.